-
Human medicines European public assessment report (EPAR): Abraxane, paclitaxel, Date of authorisation: 11/01/2008, Revision: 31, Status: Authorised
30 Jan 2025 17:24 GMT
In metastatic breast cancer, Abraxane was more effective than conventional … their first treatment for metastatic breast cancer, there was no difference between … taken other treatments for metastatic breast cancer before. Therefore, the company withdrew …
-
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
28 Jan 2025 00:55 GMT
… targeted therapy for metastatic breast cancer. Alternatively, they could … 59.8%), nab-paclitaxel (Abraxane; 24.4%), or paclitaxel … HER2-ultralow metastatic breast cancer following disease progression … or HER2-ultralow metastatic breast cancer (mBC) with prior …
-
Endocrine-Immune-Based Therapies Improved Responses in Chemo-Insensitive Patients With HR+/HER2– Breast Cancer
24 Jan 2025 18:47 GMT
… receptor 2-negative (HER2–) breast cancer (BC), with outcomes … cycles of nab-paclitaxel (Abraxane; Abraxis BioScience) and carboplatin … clinical trial of breast cancer neo-adjuvant therapy based … HR+/HER2- breast cancer-FINEST study. Cancer Communications …
-
Metronomic Capecitabine With an Aromatase Inhibitor Demonstrates Safety, Efficacy in Treatment of HR+, HER2– Metastatic Breast Cancer
15 Jan 2025 17:58 GMT
… promising option for patients with breast cancer through improved clinical efficacy and … with MBC resistant to paclitaxel (Abraxane; Abraxis BioScience, LLC) and … Administration approval overview in metastatic breast cancer. J Clin Oncol. March …
-
Neoadjuvant SHR-A1811 Produces pCRs in Early HER2+ Breast Cancer
15 Jan 2025 15:09 GMT
… the 2024 San Antonio Breast Cancer Symposium (SABCS) … to PCbHP (nab-paclitaxel [Abraxane], carboplatin, trastuzumab [Herceptin … therapy for HER2-positive breast cancer is quite [efficacious]. … of HER2-positive early breast cancer: a prospective, randomized …
-
Dr Li on Neoadjuvant SHR-A1811 in HER2+ Breast Cancer
03 Jan 2025 18:15 GMT
… treatment for HER2-positive breast cancer—the standard therapy— … patients with HER2-positive breast cancer, based on findings … or PCbHP (nab-paclitaxel [Abraxane], carboplatin, trastuzumab [Herceptin] … with early HER2-positive breast cancer, he emphasizes, a …
-
Nab-Paclitaxel Combo Improves Response vs SOC in HER2+ Breast Cancer
19 Dec 2024 22:59 GMT
Neoadjuvant nab-paclitaxel (Abraxane) in combination with … if they had bilateral breast cancer, history of other … treatment/prevention of breast cancer, and contraindications to … with HER2-positive early breast cancer (HELEN-006): a multicentre …
-
Enhertu Improves Progression-Free Survival in HR+, HER2-Low/Ultralow Metastatic Breast Cancer
12 Dec 2024 01:13 GMT
… #47;-ultralow metastatic breast cancer experienced improvements to progression- … receptor-positive metastatic breast cancer with HER2-low … (capecitabine; 59.8%), Abraxane (nab-paclitaxel; 24.4% … presented at: San Antonio Breast Cancer Conference; December 10- …
-
T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer
11 Dec 2024 19:52 GMT
… hormone receptor–positive metastatic breast cancer with HER2-low ( … 59.8%), nab-paclitaxel (Abraxane; 24.4%), or paclitaxel … Presented at: San Antonio Breast Cancer Conference; December 10-13 … or HER2-ultralow metastatic breast cancer (mBC) with prior …
-
Chemotherapy-Free Regimen Shows Promise in HER2+/HR+ Metastatic Breast Cancer
05 Dec 2024 20:44 GMT
… receptor–positive metastatic breast cancer.
Progression-free survival … receptor–positive metastatic breast cancer. The addition … , or nab-paclitaxel (Abraxane) in combination with trastuzumab … -receptor positive metastatic breast cancer – Second interim …
About
© 1995-2025